CombinatoRx, Incorporated (NASDAQ: CRXX) and Fovea Pharmaceuticals SA today announced a collaboration for the potential development and commercialization of combination drugs to treat ophthalmic diseases. The agreement unites CombinatoRx’s leadership in the systematic discovery of novel combination drug candidates with Fovea’s drug development resources and expertise in the field of ophthalmic therapeutics.
